| Description |
F 15845 is a highly effective persistent sodium current blocker. F 15845 also is a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 can be used for the research of myocardium functional impairment[1].
|
| Related Catalog |
|
| In Vitro |
F 15845 (10 nM-10 μM) concentration-dependently reduces veratrine-induced diastolic contracture with an IC50 value of 0.14 μM in isolated atria[1]. F 15845 (0.1-10 μM) preserves viability in isolated cardiomyocytes exposed to lysophosphatidylcholine (LPC)[1]. F 15845 (0.3 μM) significantly counteracts [Na+] increase during no-flow ischemia[1]. F 15845 (0.3 μM, 0-35 min) delays the reduction in [Na+], but marks and maintains upon reperfusion[1].
|
| In Vivo |
F 15845 (i.v.; 5 mg/kg) exhibits remarkable cardioprotective properties in anesthetized rat[1]. Animal Model: Rat[1] Dosage: 2.5 mg/kg, 5 mg/kg Administration: intravenously Result: Significantly reduced infarct size, decreased of troponin I levels and limited the long-term expansion of infarct size.
|
| References |
[1]. Bruno Vié, et al. 3-(R)-[3-(2-methoxyphenylthio-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine bromhydrate (F 15845) prevents ischemia-induced heart remodeling by reduction of the intracellular Na+ overload. J Pharmacol Exp Ther. 2009 Sep;330(3):696-703.
|
